Search results for "ENTEROHEPATIC CIRCULATION"

showing 8 items of 8 documents

Infant Formula Feeding Increases Hepatic Cholesterol 7α Hydroxylase (CYP7A1) Expression and Fecal Bile Acid Loss in Neonatal Piglets.

2018

BACKGROUND: During the postnatal feeding period, formula-fed infants have higher cholesterol synthesis rates and lower circulating cholesterol concentrations than their breastfed counterparts. Although this disparity has been attributed to the uniformly low dietary cholesterol content of typical infant formulas, little is known of the underlying mechanisms associated with this altered cholesterol metabolism phenotype. OBJECTIVE: We aimed to determine the molecular etiology of diet-associated changes in early-life cholesterol metabolism with the use of a postnatal piglet feeding model. METHODS: Two-day-old male and female White-Dutch Landrace piglets were fed either sow milk (Sow group) or d…

0301 basic medicineMalemedicine.medical_specialtymedicine.drug_classSwineMedicine (miscellaneous)030209 endocrinology & metabolismCholesterol 7 alpha-hydroxylaseReal-Time Polymerase Chain ReactionGene Expression Regulation EnzymologicBile Acids and Salts03 medical and health scienceschemistry.chemical_compoundFecesRandom Allocation0302 clinical medicineBlood serumInternal medicinemedicineAnimalsHumansCholesterol 7-alpha-HydroxylaseEnterohepatic circulationNutrition and DieteticsBile acidCholesterolReverse Transcriptase Polymerase Chain ReactionInfantFGF19Infant Formula030104 developmental biologyEndocrinologyMilkchemistryInfant formulaAnimals NewbornLiverFemaleSoybeansNutrient Physiology Metabolism and Nutrient-Nutrient InteractionsBreast feedingThe Journal of nutrition
researchProduct

Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine

1977

The effect of cholestyramine (12 gm/day divided into 3 doses) on the pharmacokinetics and pharmacodynamics of a single intravenouse dose (30 mg) of phenprocoumon was studied in 6 normal subjects. Cholestyramine treatment led to an increase in the rate of elimination of phenprocoumon in all. Total clearance increased 1.5- to 2-fold. The total anticoagulant effect per dose was considerably reduced during treatment with cholestyramine. Binding studies in vitro showed that phenprocoumon is strongly bound to cholestyramine and that at a given cholestyramine concentration the percentage of phenprocoumon bound remained constant over a large concentration range of phenprocoumon. The results suggest…

AdultMalePharmacologyCholestyramineAnticoagulant effectDose-Response Relationship DrugChemistryCholestyramine Resin4-HydroxycoumarinsMiddle AgedPharmacologyPhenprocoumonLiverPharmacokineticsEnterohepatic CirculationPhenprocoumonmedicineHumansPharmacology (medical)Enterohepatic circulationHalf-Lifemedicine.drugClinical Pharmacology & Therapeutics
researchProduct

CLA-Enriched Diet Containing t10,c12-CLA Alters Bile Acid Homeostasis and Increases the Risk of Cholelithiasis in Mice

2011

International audience; Mice fed a mixture of CLA containing t10,c12-CLA lose fat mass and develop hyperinsulinemia and hepatic steatosis due to an accumulation of TG and cholesterol. Because cholesterol is the precursor in bile acid (BA) synthesis, we investigated whether t10,c12-CLA alters BA metabolism. In Expt. 1, female C57Bl/6J mice were fed a standard diet for 28 d supplemented with a CLA mixture (1 g/100 g) or not (controls). In Expt. 2, the feeding period was reduced to 4, 6, and 10 d. In Expt. 3, mice were fed a diet supplemented with linoleic acid, c9,t11-CLA, or t10,c12-CLA (0.4 g/100 g) for 28 d. In Expt. 1, the BA pool size was greater in CLA-fed mice than in controls and the …

Enterohepatic circulationmedicine.medical_specialtymedicine.drug_classLinoleic acid[SDV]Life Sciences [q-bio]Blotting WesternMedicine (miscellaneous)030209 endocrinology & metabolismCholesterol 7 alpha-hydroxylasePolymerase Chain ReactionBile Acids and SaltsMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsCholelithiasisInternal medicineHyperinsulinémiemedicineHyperinsulinemiaAnimalsHomeostasisEnterohepatic circulation030304 developmental biology0303 health sciencesNutrition and DieteticsBile acidintegumentary systemCholesterolalpha-Linolenic Acidfood and beveragesmedicine.diseaseDietary FatsBile Salt Export PumpMice Inbred C57BLCholesterol 7-alpha hydroxylaseCholesterolEndocrinologyMetabolismLiverchemistryNutrient physiologyFemalelipids (amino acids peptides and proteins)Steatosis[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

Pharmacokinetics and bioavailability of diclofenac in the rat.

1991

Diclofenac sodium is a widely used drug with interesting absorption and disposition features when administered to laboratory animals. The present study was undertaken to assess the pharmacokinetics of the drug after iv and gastrointestinal dosing to rats. Renal excretion of unchanged drug was negligible, but biliary excretion of the drug (unchanged and conjugated) was detected in bile duct-cannulated rats; it accounted for 27.2 and 31.2% of the total dose following iv and intraduodenal administration, respectively. Most of the drug excreted in the bile was conjugated diclofenac; unchanged drug accounted for only 4.7 and 5.4% of total diclofenac excreted in the bile after iv and intraduodena…

Malemedicine.medical_specialtyDiclofenacDuodenumAdministration OralBiological AvailabilityPharmacologyIntestinal absorptionInjectionsDiclofenacPharmacokineticsOral administrationInternal medicinemedicineAnimalsBilePharmacology (medical)General Pharmacology Toxicology and PharmaceuticsEnterohepatic circulationChemistryRats Inbred StrainsDiclofenac SodiumBioavailabilityRatsstomatognathic diseasesmedicine.anatomical_structureEndocrinologyIntestinal AbsorptionData Interpretation StatisticalInjections IntravenousDuodenummedicine.drugJournal of pharmacokinetics and biopharmaceutics
researchProduct

A Model‐Based Workflow to Benchmark the Clinical Cholestasis Risk of Drugs

2021

We present a generic workflow combining physiology-based computational modeling and in vitro data to assess the clinical cholestatic risk of different drugs systematically. Changes in expression levels of genes involved in the enterohepatic circulation of bile acids were obtained from an in vitro assay mimicking 14 days of repeated drug administration for 10 marketed drugs. These changes in gene expression over time were contextualized in a physiology-based bile acid model of glycochenodeoxycholic acid. The simulated drug-induced response in bile acid concentrations was then scaled with the applied drug doses to calculate the cholestatic potential for each compound. A ranking of the cholest…

MalePHARMACOKINETICSAZATHIOPRINEAzathioprineBioinformatics030226 pharmacology & pharmacyWorkflowchemistry.chemical_compound0302 clinical medicinePARACETAMOLPharmacology (medical)Enterohepatic circulationmedia_common0303 health sciencesCholestasisBile acidMiddle Aged3. Good healthBenchmarkingLiverPharmaceutical PreparationsSINGLEDrug developmentFemaleVALPROATEmedicine.drugAdultDrugDrug-Related Side Effects and Adverse ReactionsDICLOFENAC SODIUMmedicine.drug_classmedia_common.quotation_subjectModels BiologicalYoung Adult03 medical and health sciencesCholestasisPharmacokineticsSpheroids CellularmedicineGlycochenodeoxycholic acidAnimalsHumansddc:610030304 developmental biologyPharmacologybusiness.industrymedicine.diseasechemistryACETAMINOPHENbusinessClinical Pharmacology & Therapeutics
researchProduct

A Physiology-Based Model of Human Bile Acid Metabolism for Predicting Bile Acid Tissue Levels After Drug Administration in Healthy Subjects and BRIC …

2019

Drug-induced liver injury (DILI) is a matter of concern in the course of drug development and patient safety, often leading to discontinuation of drug-development programs or early withdrawal of drugs from market. Hepatocellular toxicity or impairment of bile acid (BA) metabolism, known as cholestasis, are the two clinical forms of DILI. Whole-body physiology-based modelling allows a mechanistic investigation of the physiological processes leading to cholestasis in man. Objectives of the present study were: (1) the development of a physiology-based model of the human BA metabolism, (2) population-based model validation and characterisation, and (3) the prediction and quantification of alter…

0301 basic medicineEXPRESSIONPBPKLIVERmedicine.drug_classPhysiologyBenign Recurrent Intrahepatic CholestasisPopulationBIOMARKERScomputational modellingPhysiologyDIAGNOSISlcsh:Physiology03 medical and health scienceschemistry.chemical_compoundPHARMACOKINETIC MODEL0302 clinical medicineCholestasisPhysiology (medical)Glycochenodeoxycholic acidMedicineddc:610educationEnterohepatic circulationKINETICSOriginal ResearchLiver injuryINTRAHEPATIC CHOLESTASISbile acidseducation.field_of_studyBile acidlcsh:QP1-981business.industryBRIC type 2medicine.diseaseTRANSPORTERS3. Good health030104 developmental biologychemistryToxicitySIMULATION030211 gastroenterology & hepatologyENTEROHEPATIC CIRCULATIONDILIbusinesscholestasisFrontiers in Physiology
researchProduct

Pharmacokinetics, bioavailability and absorption of flumequine in the rat.

1999

Abstract The study demonstrates that the oral extent of bioavailability of flumequine in the rat, relative to the intravenous injection, is complete (0.94±0.04) and not significantly different from that found by the intraduodenal route (0.95±0.04). The rate of oral bioavailability, however, is slow ( k a =1.20±0.07 h −1 ; T max =2.0 h), but enough to maintain plasma levels above the minimal inhibitory concentration of the most common pathogens for an extended period of time (about 10 h). The reason for the oral absorption slowness could be a slow gastric emptying, an adsorption to the gastric mucosae, a precipitation in the gastric medium or any other feature concerning the stomach as the i…

MaleDuodenumPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyModels BiologicalRandom AllocationPharmacokineticsAnti-Infective AgentsOral administrationEnterohepatic CirculationmedicineAnimalsRats WistarEnterohepatic circulationAntibacterial agentGastric emptyingChemistryStomachGeneral MedicineBioavailabilityRatsmedicine.anatomical_structureIntestinal AbsorptionFlumequineQuinolizinesBiotechnologymedicine.drugFluoroquinolonesEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

Synthese, Verteilung und Ausscheidung von 14C markiertem 2-Phenyl-3-methyl-tetrahydro-1,4-oxazin (Preludin)

1958

A radioactive preludin preparation, C14 labelled on the 2-carbon of the tetrahydrooxazine ring, was injected into mice in doses of 100 mg/kg s.c. and rats in doses of 10 mg/kg i.v. The radioactivity of the tissues and excreta was followed for 48 hours. An activity concentration surpassing the average body concentration was obtained for a short time in the lungs and for a longer time in kidneys, liver and in the wall of stomach and small intestine. 95–99% of the total activity is found in the urine. The kidney excretion is virtually finished at the end of 8 hours; 1–5% appear after the 8th hour in faeces. No radioactivity was obtained from the expired CO2. The main excretion organs are kidne…

Pharmacologymedicine.medical_specialtyKidneyChemistryStomachGeneral MedicineUrineSmall intestineExcretionmedicine.anatomical_structureEndocrinologyInternal medicineActivity concentrationmedicineEnterohepatic circulationFecesNaunyn-Schmiedebergs Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct